GLP-1 Receptor Agonists (Semaglutide Focus)

Glucagon‑like peptide‑1 receptor agonists (GLP‑1 RAs) are peptide‑based drugs used for type 2 diabetes and chronic weight management, with semaglutide as a leading agent.678 They have a substantial randomized‑trial and meta‑analysis evidence base demonstrating clinically meaningful reductions in body weight, glycated hemoglobin, and cardiometabolic risk markers.786

Semaglutide is a synthetic acylated GLP‑1 analogue with modifications that increase albumin binding and proteolytic stability, extending its half‑life to enable once‑weekly injection or daily oral dosing.67 It derives conceptually from endogenous GLP‑1, an incretin hormone secreted by intestinal L‑cells in response to nutrient intake.

GLP‑1 RAs enhance glucose‑dependent insulin secretion, suppress inappropriate glucagon release, slow gastric emptying, and act on central appetite‑regulation pathways to reduce energy intake.76 Across trials and meta‑analyses, these mechanisms translate into consistent weight loss, improved glycemic control, and favorable effects on blood pressure and some lipid parameters.867

Multiple phase 3 programs, including PIONEER (oral semaglutide) and STEP (injectable semaglutide for obesity), have shown significant reductions in HbA1c and body weight versus placebo in diverse populations.86 A 2025 systematic review of 47 randomized trials confirmed that GLP‑1 RAs, particularly semaglutide, produced the largest average weight loss among agents in the class.7

• Type 2 diabetes management and glycemic durability67
• Obesity and overweight in people with and without diabetes (including prediabetes cohorts)87
• Cardiovascular and renal outcome trials in high‑risk populations
• Combination regimens and comparison with dual agonists (e.g. tirzepatide)7

While efficacy is robust, gastrointestinal adverse events (nausea, vomiting, diarrhea) are common and can limit adherence at higher doses.687 Long‑term safety beyond several years, especially in broad real‑world obesity populations and in combination with other incretin‑based agents, is still being clarified.87

1. Rosenstock J et al. PIONEER 1: Oral semaglutide monotherapy vs placebo in type 2 diabetes. Diabetes Care. 2019.6
2. Zhao X et al. Efficacy of GLP‑1 receptor agonists on weight, BMI, and waist circumference: Systematic review and meta‑analysis of 47 RCTs. Diabetes Care. 2025.7
3. Wadden TA et al. STEP‑10: Once‑weekly semaglutide 2.4 mg in obesity with prediabetes—phase 3 trial. Lancet Diabetes Endocrinol. 2024.8